Raman Spectroscopy and Exosome-Based Machine Learning Predicts the Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer
Analytical Chemistry · 2025
DOI: 10.1021/acs.analchem.4c05833 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2025. Verfasst von Yining Jia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, Shandong 250033, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Exosomes, Neoadjuvant Therapy, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Taishan Scholar Project of Shandong Province, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Early prediction of the neoadjuvant therapy efficacy for HER2-positive breast cancer is crucial for personalizing treatment and enhancing patient outcomes. Exosomes, which play a role in tumor development and treatment response, are emerging as potential biomarkers for cancer diagnosis and efficacy prediction. Despite their promise, current exosome detection and isolation methods are cumbersome and time-consuming and often yield limited purity and quantity. In this study, we employed Raman spectroscopy to analyze the molecular changes in exosomes from the sera of HER2-positive breast cancer patients before and after two cycles of neoadjuvant therapy. Utilizing machine learning techniques (PCA, LDA, and SVM), we developed a predictive model with an AUC value exceeding 0.89. Additionally, we introduced an innovative HER2-positive exosome capture and detection system, termed Magnetic beads@HER2-Exos@HER2-SERS detection nanoprobes (HER2-MEDN). This system enabled us to efficiently extract and analyze HER2-positive exosomes, refining our predictive model to achieve an accuracy greater than 0.94. Our study has demonstrated the potential of the HER2-MEDN system in accurately predicting early treatment response, offering novel insights and methodologies for assessing the efficacy of neoadjuvant therapy in HER2-positive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, Shandong 250033, China.
- Institute of Translational Medicine of Breast Disease Prevention and Treatment, Shandong University, Jinan, Shandong 250033, China.
- School of Mathematics, Shandong University, Jinan, Shandong 250100, China.
ORCID-Profile: Zhigang Yu, Chao Zheng
Förderung
- China Postdoctoral Science Foundation
- Taishan Scholar Project of Shandong Province
- Natural Science Foundation of Shandong Province
- Jinan Clinical Medical Science and technology Innovation plan
Zitieren
APA
Jia, Y., Li, Y., Bai, X., Liu, L., Shan, Y., Wang, F., Yu, Z., & Zheng, C. (2025). Raman Spectroscopy and Exosome-Based Machine Learning Predicts the Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.4c05833
Vancouver
Jia Y, Li Y, Bai X, Liu L, Shan Y, Wang F, et al. Raman Spectroscopy and Exosome-Based Machine Learning Predicts the Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer. Analytical Chemistry. 2025. doi:10.1021/acs.analchem.4c05833
BibTeX
@article{Jia2025,
author = {Jia, Yining and Li, Yongqi and Bai, Xintong and Liu, Liyuan and Shan, Ying and Wang, Fei and Yu, Zhigang and Zheng, Chao},
title = {Raman Spectroscopy and Exosome-Based Machine Learning Predicts the Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer},
journal = {Analytical Chemistry},
year = {2025},
doi = {10.1021/acs.analchem.4c05833}
}
EUVIMED